Interleukin-6 in bone metastasis and cancer progression

European Journal of Cancer

Volumn 46, Issue 7, 2010, Pages 1223-1231

  Ara, Tasnim ^a   DeClerck, Yves A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bone metastasis; Interleukin 6; Tumor microenvironment

Indexed keywords

531 201; BORTEZOMIB; CNTO 328; CYTOKINE RECEPTOR ANTAGONIST; DENOSUMAB; DEXAMETHASONE; DIACLONE; INCB 20; INTERLEUKIN 6; INTERLEUKIN 6 INHIBITOR; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; JANUS KINASE INHIBITOR; LENALIDOMIDE; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B E8; NSC 74859; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; S31 201; SOLUBLE INTERLEUKIN 6 RECEPTOR; SORAFENIB; STAT3 PROTEIN; SUNITINIB; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTHRITIS; ARTICLE; BONE METASTASIS; CANCER GROWTH; CARCINOGENIC ACTIVITY; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DRUG TARGETING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; MEDULLOBLASTOMA; MENTAL DISEASE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SKIN INFECTION; TUMOR; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; BONE NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; NEOPLASM METASTASIS; OSTEOLYSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77950690023     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.026     Document Type: Article

References (104)

1. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 350 (2004) 1655-1664
2. Chambers A.F., Groom A.C., and MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2 (2002) 563-572
3. Reddi A.H., Roodman D., Freeman C., et al. Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 18 (2003) 190-194
4. Hattori K., Heissig B., and Rafii S. The regulation of hematopoietic stem cell and progenitor mobilization by chemokine SDF-1. Leuk Lymphoma 44 (2003) 575-582
5. Juarez J., Bendall L., and Bradstock K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des 10 (2004) 1245-1259
6. Wilson A., and Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 6 (2006) 93-106
7. Geminder H., Sagi-Assif O., Goldberg L., et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 167 (2001) 4747-4757
8. Taichman R.S., Cooper C., Keller E.T., et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62 (2002) 1832-1837
9. Strahm B., Durbin A.D., Sexsmith E., et al. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis (2007) 1-10
10. Teoh G., and Anderson K.C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 11 (1997) 27-42
11. Sohara Y., Shimada H., Minkin C., et al. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res 65 (2005) 1129-1135
12. Blouin S., Basle M.F., and Chappard D. Interactions between microenvironment and cancer cells in two animal models of bone metastasis. Br J Cancer 98 (2008) 809-815
13. Yoneda T., and Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328 (2005) 679-687
14. Scheller J., and Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 195 (2006) 173-183
15. Hong D.S., Angelo L.S., and Kurzrock R. Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer 110 (2007) 1911-1928
16. Naka T., Nishimoto N., and Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 4 Suppl 3 (2002) S233-S242
17. Pedersen B.K., and Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88 (2008) 1379-1406
18. Eder K., Baffy N., Falus A., et al. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 58 (2009) 727-736
19. Howren M.B., Lamkin D.M., and Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71 (2009) 171-186
20. Yamasaki K., Taga T., Hirata Y., et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241 (1988) 825-828
21. Hilbert D.M., Kopf M., Mock B.A., et al. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 182 (1995) 243-248
22. Knupfer H., and Preiss R. SIL-6R: more than an agonist?. Immunol Cell Biol 86 (2008) 87-91
23. Holub M.C., Szalai C., Polgar A., et al. Generation of 'truncated' interleukin-6 receptor (IL-6R) mRNA by alternative splicing; a possible source of soluble IL-6R. Immunol Lett 68 (1999) 121-124
24. Peters M., Meyer zum Buschenfelde K.H., and Rose-John S. The function of the soluble IL-6 receptor in vivo. Immunol Lett 54 (1996) 177-184
25. Rose-John S., Scheller J., Elson G., et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80 (2006) 227-236
26. Chalaris A., Rabe B., Paliga K., et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110 (2007) 1748-1755
27. Briso E.M., Dienz O., and Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol 180 (2008) 7102-7106
28. Scheller J., Ohnesorge N., and Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 63 (2006) 321-329
29. Richards P.J., Nowell M.A., Horiuchi S., et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum 54 (2006) 1662-1672
30. Heinrich P.C., Behrmann I., Haan S., et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
31. Murray P.J. The JAK-STAT signaling pathway: input and output integration. J Immunol 178 (2007) 2623-2629
32. Hu L., Shi Y., Hsu J.H., et al. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101 (2003) 3126-3135
33. Zhang J., Li Y., and Shen B. PI3-K/Akt pathway contributes to IL-6-dependent growth of 7TD1 cells. Cancer Cell Int 3 (2003) 1
34. Jee S.H., Chu C.Y., Chiu H.C., et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol 123 (2004) 1169-1175
35. Liu X.H., Kirschenbaum A., Yao S., et al. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology 146 (2005) 1991-1998
36. Ara T., Song L., Shimada H., et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 69 (2009) 329-337
37. Hall C.L., and Keller E.T. The role of Wnts in bone metastases. Cancer Metastasis Rev 25 (2006) 551-558
38. Gunn W.G., Conley A., Deininger L., et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24 (2006) 986-991
39. Kang Y., Siegel P.M., Shu W., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3 (2003) 537-549
40. Guise T.A., and Chirgwin J.M. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res (2003) S32-S38
41. Yamamoto T., Matsuda T., Muraguchi A., et al. Cross-talk between IL-6 and TGF-beta signaling in hepatoma cells. FEBS Lett 492 (2001) 247-253
42. Lee H., Herrmann A., Deng J.H., et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15 (2009) 283-293
43. Niu G., Wright K.L., Ma Y., et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25 (2005) 7432-7440
44. Mora L.B., Buettner R., Seigne J., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62 (2002) 6659-6666
45. Bromberg J.F., Wrzeszczynska M.H., Devgan G., et al. Stat3 as an oncogene. Cell 98 (1999) 295-303
46. Hideshima T., Chauhan D., Richardson P., et al. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 23 (2005) 6345-6350
47. Fukaya Y., Shimada H., Wang L.C., et al. Identification of Gal-3 binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J Biol Chem 27 (2008) 18573-18581
48. Ogata A., Chauhan D., Teoh G., et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159 (1997) 2212-2221
49. Smith P.C., Hobisch A., Lin D.L., et al. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12 (2001) 33-40
50. Bollrath J., Phesse T.J., von Burstin V.A., et al. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15 (2009) 91-102
51. Niu G., Bowman T., Huang M., et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21 (2002) 7001-7010
52. Quintanilla-Martinez L., Kremer M., Specht K., et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 162 (2003) 1449-1461
53. Gritsko T., Williams A., Turkson J., et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12 (2006) 11-19
54. Barre B., Vigneron A., Perkins N., et al. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 13 (2007) 4-11
55. Shain K.H., Yarde D.N., Meads M.B., et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69 (2009) 1009-1015
56. Blanchard F., Duplomb L., Baud'huin M., et al. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev 20 (2009) 19-28
57. O'Brien C.A., Gubrij I., Lin S.C., et al. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1, 25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274 (1999) 19301-19308
58. Guillen C., de Gortazar A.R., and Esbrit P. The interleukin-6/soluble interleukin-6 receptor system induces parathyroid hormone-related protein in human osteoblastic cells. Calcif Tissue Int 75 (2004) 153-159
59. Erices A., Conget P., Rojas C., et al. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp Cell Res 280 (2002) 24-32
60. Kim K., Lee J., Kim J.H., et al. Protein inhibitor of activated STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and osteoclast-associated receptor. J Immunol 178 (2007) 5588-5594
61. Bommert K., Bargou R.C., and Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 42 (2006) 1574-1580
62. Itoh S., Udagawa N., Takahashi N., et al. A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. Bone 39 (2006) 505-512
63. Legendre F., Dudhia J., Pujol J.P., et al. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 278 (2003) 2903-2912
64. Xie T.X., Huang F.J., Aldape K.D., et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66 (2006) 3188-3196
65. Kim M.Y., Oskarsson T., Acharyya S., et al. Tumor self-seeding by circulating cancer cells. Cell 139 (2009) 1315-1326
66. Fan Y., Ye J., Shen F., et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 28 (2008) 90-98
67. Kujawski M., Kortylewski M., Lee H., et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118 (2008) 3367-3377
68. Wei L.H., Kuo M.L., Chen C.A., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22 (2003) 1517-1527
69. Dankbar B., Padro T., Leo R., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95 (2000) 2630-2636
70. Huang S.P., Wu M.S., Shun C.T., et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 11 (2004) 517-527
71. Mantovani A., Allavena P., Sica A., et al. Cancer-related inflammation. Nature 454 (2008) 436-444
72. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7 (2007) 41-51
73. Egler R.A., Burlingame S.M., Nuchtern J.G., et al. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res 14 (2008) 7028-7034
74. Kovacs E. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 55 (2001) 391-396
75. Robak T., Wierzbowska A., Blasinska-Morawiec M., et al. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Mediators Inflamm 8 (1999) 277-286
76. Stasi R., Brunetti M., Parma A., et al. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 82 (1998) 1860-1866
77. Dowdall J.F., Winter D.C., Andrews E., et al. Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation?. J Surg Res 107 (2002) 1-6
78. Jones S.A., Horiuchi S., Topley N., et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15 (2001) 43-58
79. Zaki M.H., Nemeth J.A., and Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111 (2004) 592-595
80. Voorhees P.M., Chen Q., Kuhn D.J., et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 13 (2007) 6469-6478
81. Voorhees P.M., Chen Q., Small G.W., et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 145 (2009) 481-490
82. Moreau P., Harousseau J.L., Wijdenes J., et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 109 (2000) 661-664
83. Emery P., Keystone E., Tony H.P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008) 1516-1523
84. Smolen J.S., Beaulieu A., Rubbert-Roth A., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371 (2008) 987-997
85. Genovese M.C., McKay J.D., Nasonov E.L., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58 (2008) 2968-2980
86. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371 (2008) 998-1006
87. Jones G., Sebba A., Gu J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69 (2010) 88-96
88. Aggarwal B.B., Sethi G., Ahn K.S., et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091 (2006) 151-169
89. Burger R., Le Gouill S., Tai Y.T., et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 8 (2009) 26-35
90. Siddiquee K., Zhang S., Guida W.C., et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104 (2007) 7391-7396
91. Lin L., Amin R., Gallicano G.I., et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 28 (2009) 961-972
92. Yang F., Van Meter T.E., Buettner R., et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 7 (2008) 3519-3526
93. Strumberg D., Clark J.W., Awada A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12 (2007) 426-437
94. Gridelli C., Maione P., Del Gaizo F., et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 12 (2007) 191-200
95. Xin H., Zhang C., Herrmann A., et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69 (2009) 2506-2513
96. Feldman D.R., Baum M.S., Ginsberg M.S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 1432-1439
97. Richardson P.G., Mitsiades C., Hideshima T., et al. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 6 (2006) 1165-1173
98. Lu L., Payvandi F., Wu L., et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77 (2009) 78-86
99. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
100. Oades G.M., Senaratne S.G., Clarke I.A., et al. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170 (2003) 246-252
101. Perry C.M., and Figgitt D.P. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 64 (2004) 1197-1211
102. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 9 Suppl. 4 (2004) 14-27
103. Body J.J., Facon T., Coleman R.E., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12 (2006) 1221-1228
104. Fizazi K., Lipton A., Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27 (2009) 1564-1571